Revenue: As of FY2025 Q2, the actual value is USD 120 K, missing the estimate of USD 212.5 K.EPS: As of FY2025 Q2, the actual value is USD -2.45, missing the estimate of USD -1.8575.EBIT: As of FY2025 Q2, the actual value is USD -15.85 M.<h3>Segment Revenue</h3><ul><li>Product Revenue, Net: $120 thousand for the three months ended June 30, 2025, compared to $1,104 thousand for the same period in 2024. For the six months ended June 30, 2025, product revenue was $288 thousand, compared to $1,686 thousand for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Cost of Goods Sold: $107 thousand for the three months ended June 30, 2025, compared to $62 thousand for the same period in 2024. For the six months ended June 30, 2025, cost of goods sold was $121 thousand, compared to $141 thousand for the same period in 2024.</li><li>Research and Development Expenses: $10,256 thousand for the three months ended June 30, 2025, compared to $8,032 thousand for the same period in 2024. For the six months ended June 30, 2025, research and development expenses were $14,810 thousand, compared to $19,433 thousand for the same period in 2024.</li><li>Selling, General and Administrative Expenses: $5,609 thousand for the three months ended June 30, 2025, compared to $9,450 thousand for the same period in 2024. For the six months ended June 30, 2025, selling, general and administrative expenses were $11,308 thousand, compared to $22,715 thousand for the same period in 2024.</li><li>Net Loss: $19,187 thousand for the three months ended June 30, 2025, compared to $8,299 thousand for the same period in 2024. For the six months ended June 30, 2025, net loss was $26,441 thousand, compared to $35,090 thousand for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: $24,618 thousand for the six months ended June 30, 2025, compared to $40,880 thousand for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $13,339 thousand for the six months ended June 30, 2025, compared to $31,930 thousand for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Inventory Write-Downs: $95 thousand for the three months ended June 30, 2025, compared to $0 for the same period in 2024. For the six months ended June 30, 2025, inventory write-downs were $95 thousand, compared to $45 thousand for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company is focusing on the commercialization of IGALMI® and the development of BXCL501 for the acute treatment of agitation associated with schizophrenia, bipolar disorders, and Alzheimer’s disease. The company is also advancing its SERENITY At-Home pivotal Phase 3 trial and plans to generate additional Phase 3 efficacy and safety data in its TRANQUILITY In-Care trial.</li><li>Non-Core Business: The company has deprioritized the development of BXCL701 programs, except for certain ongoing trials, and is evaluating strategic options for its subsidiary, OnkosXcel Therapeutics.</li><li>Priority: The company is prioritizing the development and commercialization of BXCL501 and IGALMI® in the at-home setting and care facilities, with a focus on generating additional clinical data to support regulatory submissions and potential label expansions.</li></ul>

Bioxcel Therap | 10-Q: FY2025 Q2 Revenue Misses Estimate at USD 120 K